linjc16/ctgov huggingface dataset:
Whole Person Care Research Program of the Suicide Cases Consultative Services

Study Overview
=================
Brief Summary
-----------------
This project aims to provide more treatment options to suicide patients to further enhance the holistic medical services in Far Eastern Memorial Hospital. It focuses on high-risk cases, especially those whose suicidal behaviors are triggered by interpersonal/or emotional problems because psychological counseling or interpersonal growth groups of services have been shown to be beneficial to this population.

Official Title
-----------------
Whole Person Care Research Program of the Suicide Cases Consultative Services

Conditions
-----------------
Suicide

Intervention / Treatment
-----------------
* Other: Lifestyle counseling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: above 20 years old, survivors from suicide. Exclusion Criteria: under 20 years old prisoner suffer from a serious illness foreigner/ can't speak Chinese the people who can't express themselves can not be interviewed in FEMH people with severe physical or psychological symptoms

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Lifestyle counseling<br> | Other: Lifestyle counseling<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient's satisficaction questionaire | A form for patients record their comment of each meeting with psychologist and other group member in a supportive group. | six weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Individual Counseling service, Group Counseling service
Cornell Translational Behavioral Science Research Consortium: Asthma Qualitative Study

Study Overview
=================
Brief Summary
-----------------
To explore and illuminate the cultural, social, and psychological factors that either facilitate or serve as barriers to behavioral change in asthma patients.

Detailed Description
-----------------
Through a series of open-ended questions we will explore and build a better understanding of how different patient populations view asthma and the difficulties they face in changing behavior. In addition the responses to such questions should help us to better understand and anticipate some of the barriers and issues that participants may face in successfully changing their behaviors. The second objective is to use the responses obtained to inform how an intervention of positive affect induction and self-affirmation should be operationalized and tailored.

Official Title
-----------------
Cornell Translational Behavioral Science Research Consortium: Asthma Qualitative Study

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Behavioral: Semi-structured, open-ended interviews


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will be eligible for this study if their physicians consider them medically able to participate, if they are 18 years of age or older, and if they have a diagnosis of mild to moderate asthma based on the NHLBI Asthma Expert Panel's classification system which rates symptoms, frequency of exacerbations, nocturnal attacks, activity restriction, use of medications, and pulmonary function. Exclusion Criteria: Patients will be excluded from this study for the following reasons: If they are unable to walk several blocks for whatever reason; If they have musculoskeletal or neurological deficits that preclude increased physical activity; If they have other pulmonary diseases; If they have cardiac disease or other severe comorbidity; If they are unable to provide informed consent because of cognitive deficits; If they refuse to participate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Semi-structured, open-ended interviews|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Behavior change, Physical activity, Risk reduction
Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate if treatment of CMV infection by antiviral drug Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local CMV infection in tumor tissue. The investigators' hypothesis states that CMV infection promotes tumor development and disease progression and inhibits immune responses against the tumor.

Official Title
-----------------
A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.

Conditions
-----------------
Glioblastoma Multiforme, Cytomegalovirus Infection

Intervention / Treatment
-----------------
* Drug: Valganciclovir (Valcyte)
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Glioblastoma grade IV Cytomegalovirus detected in tumor At least 90% resection of tumor Exclusion Criteria: Decreased kidney function Pregnancy Neutropenia Thrombocytopenia Patient not tolerating the drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Valganciclovir<br> | Drug: Valganciclovir (Valcyte)<br> <br> |
| Placebo Comparator: Placebo<br> | Other: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor size |  | Week twelve | 
| Tumor size |  | Week twenty four | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease status |  | 24 months | 
| Patient survival |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glioblastoma multiforme, cytomegalovirus infection, antiviral treatment, valganciclovir
Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty

Study Overview
=================
Brief Summary
-----------------
Patients receiving BNP or nitroglycerin (IV) during the angioplasty procedure. 24 h after the procedure, vascular reactivity will be re-examined using the brachial artery flow-mediated dilatation study. Blood assays for ET-1, pro-BNP, and various inflammatory markers will be checked before and 24 h after the procedure. It is our hypothesis that endothelial function will be better in the BNP treated patients compared to the NTG treated patients

Official Title
-----------------
Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Drug: Nesiritide,


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:coronary artery disease - Exclusion Criteria:CHF and/or reduced LV function, or renal failure with Creatinine >2mg% -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nesiritide,|PCI|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FMD |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endothelial disfunction, BNP, PCI, coronary artery disease
OLIF25™ /OLIF51™ Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this single-arm observational study is to observe and document clinical outcomes of the OLIF25™ and OLIF51™ procedures in patients diagnosed with degenerative disc disease or degenerative scoliosis, and report the rate of adverse events of interest through the 24 months follow-up visit.

Official Title
-----------------
A Multi-Center, Prospective, Observational Study to Assess Outcomes for Patients Treated for Lumbar Spinal Conditions Using an OLIF25™ and/or OLIF51™Approach

Conditions
-----------------
Degenerative Disc Disease, Scoliosis

Intervention / Treatment
-----------------
* Procedure: Oblique Lateral Interbody Fusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is 18 years of age or older. Patient agrees to participate in the study and is able to sign the informed consent/data release form. Patient is undergoing surgery from L2-L5 for OLIF25™ and/or from L5-S1 for OLIF51™ for degenerative disc disease or degenerative scoliosis. Exclusion Criteria: 1. Illiterate or vulnerable patients (e.g. minors, participants incapable of judgment).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Back and Leg Pain Measured by Visual Analogue Scales (VAS) |  | 24 months | 
| Oswestry Disability Index (ODI) |  | 24 months | 
| European Quality of Life-5 Dimensions (EQ-5D) self-report questionnaire |  | 24 months | 
| Neurological deficits assessed by neurological status | Neurological status is based on seven components of measurements: Motor function; Sensory function; Deep Tendon reflexes; Sympathetic Exam; Claudication; Urinary bladder retention/Bowel retention; and Sexual Dysfunction. | 24 months | 
| Rate of adverse events |  | 24 months |
J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Study Overview
=================
Brief Summary
-----------------
The primary objective of this post marketing survey is to prospectively investigate patients with hypertension treated with Micardis Tablets (hereinafter this drug) in routine clinical settings for 3 years in order to determine the following: Adverse events and adverse drug reactions under long-term use Blood pressure measurements during the survey period Determination of the incidence of cerebrovascular and cardiovascular events under use of this drug in routine clinical settings Patient's lifestyle and background factors that are considered to affect the occurrence of cerebrovascular and cardiovascular events

Official Title
-----------------
Special Survey (Survey on Cerebrovascular and Cardiovascular Events Under Long-term Use) of Micardis Tablets (Telmisartan)

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Telmisartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Hypertension patients unadministered Micardis. Exclusion criteria: Patients with a history of hypersensitivity to any ingredient of this product. Pregnant woman or possibly pregnant woman Patients with extremely poor bile secretion or patients with serious hepatic disorder

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with hypertension<br> | Drug: Telmisartan<br>* Oral administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients With Cerebrovascular(CeV) and Cardiovascular (CaV) Events |  | 3 years after initiation of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in Systolic Blood Pressure at 6 Months |  | initiation and 6 months | 
| Change From Baseline in Diastolic Blood Pressure at 6 Months |  | initiation and 6 months | 
| Change From Baseline in Systolic Blood Pressure at 12 Months |  | initiation and 12 months | 
| Change From Baseline in Diastolic Blood Pressure at 12 Months |  | initiation and 12 months | 
| Change From Baseline in Systolic Blood Pressure at 24 Months |  | initiation and 24 months | 
| Change From Baseline in Diastolic Blood Pressure at 24 Months |  | initiation and 24 months | 
| Change From Baseline in Systolic Blood Pressure at 36 Months |  | initiation and 36 months | 
| Change From Baseline in Diastolic Blood Pressure at 36 Months |  | initiation and 36 months |
Hydrogen Inhalation for Health and Exercise Performance

Study Overview
=================
Brief Summary
-----------------
In this randomized double-blind, placebo-controlled, crossover pilot trial, we evaluated the effects of 7-day H2 inhalation on exercise performance outcomes and serum hormonal and inflammation profiles in a cohort of young men and women.

Detailed Description
-----------------
All participants were allocated to receive either gaseous hydrogen (4%) or placebo (room air) by 20-min once-per-day inhalation for 7 days, with wash-out period of 7 days to prevent the residual effects of interventions across study periods. The primary treatment outcome was the change in running time-to-exhaustion from baseline to day 7. Additionally, assessment of other exercise performance endpoints and clinical chemistry biomarkers were performed at baseline and after 7 days after each intervention.

Official Title
-----------------
Hydrogen Inhalation for Health and Exercise Performance

Conditions
-----------------
Exercise Performance

Intervention / Treatment
-----------------
* Other: Placebo
* Other: Hydrogen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 -35 years Body mass index 20 - 25 kg/m2 Free of major diseases Physically active Must be able to give written informed consent Exclusion Criteria: Use of any dietary supplements within 4 weeks before study commences Abnormal values for lab clinical chemistry (> 2 SD)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Room air for inhalation | Other: Placebo<br>* Inhalation of room air for 20 min per day during 7 days<br>|
| Experimental: Hydrogen<br>Hydrogen (4%) for inhalation | Other: Hydrogen<br>* Inhalation of 4% hydrogen for 20 min per day during 7 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in exercise performance | Running time-to-exhaustion | Change from baseline running time-to-exhaustion at 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in exercise performance | Maximal voluntary isometric strength | Change from baseline maximal voluntary isometric strength at 7 days | 
| Change in clinical chemistry biomarker | Insulin | Change from baseline serum insulin at 7 days | 
| Change in clinical chemistry biomarker | Ghrelin | Change from baseline serum ghrelin at 7 days |
Can Structured Education Promote Physical Activity in Those Identified With an Increased Risk of Developing Diabetes

Study Overview
=================
Brief Summary
-----------------
This study is a three-armed randomised controlled trial that aims to determine the effect of a structured educational programme on physical activity levels and glucose tolerance in individuals with impaired glucose tolerance (IGT). The educational programme is designed to promote physical activity by targeting perceptions and knowledge of IGT, exercise self-efficacy, and self-regulatory skills. The study will also investigate whether the effectiveness of the educational programme at promoting self-regulatory skills and physical activity is enhanced by the inclusion of a pedometer and personalised step/day goals.

Official Title
-----------------
A Randomised Controlled Trial to Investigate the Effect of a Structured Educational Programme on Physical Activity Levels and Glucose Tolerance in People With Impaired Glucose Tolerance

Conditions
-----------------
Prediabetic State

Intervention / Treatment
-----------------
* Behavioral: PREPARE with pedometer
* Behavioral: PREPARE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 2-h blood glucose ≥ 7.8 mmol/l and < 11.1 mmol/l Fasting plasma glucose < 7 mmol/l BMI ≥ 25 kg/m2 (or 23 kg/m2 for those from a South Asian ethnic origin) Aged 18 or over Exclusion Criteria: Taking medication known to significantly interfere with glucose tolerance Participating in regular vigorous physical activity Unable to participate in moderate intensity physical activity Pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Behavioral: PREPARE with pedometer<br>* Structured educational programme with pedometer use<br>|
| Active Comparator: 2<br> | Behavioral: PREPARE<br>* Structured educational programme<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2-hour glucose |  | 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pedometer counts, Fasting glucose, total cholesterol, HDL-cholesterol, LDL- cholesterol, TNFα, IL-6, CRP, systolic and diastolic blood pressure, body mass, waist circumference, BMI, physical activity, psychological determinants |  | Pedometer counts, 7 days ; everything else, 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise
Pilot Study of Fructose for Sickle Cell Crisis

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate the efficacy and tolerability of fructose administered every 6 hours for up to 72 hours to patients in active sickle cell crisis. II. Obtain tolerability information in selected patients treated with fructose for more than 72 hours.

Detailed Description
-----------------
PROTOCOL OUTLINE: In the first part of the study, patients are block-randomized (3:1) to a single intravenous dose of fructose or placebo. The dose of fructose is escalated in each successive group after tolerability data are evaluated. In the second part of the study, patients are randomly assigned (1:1) to fructose or placebo administered intravenously every 6 hours for 72 hours. The dose of fructose is the highest well-tolerated dose determined in Study 1 or the most tolerated dose for the patient. Patients who just completed Study 1 may participate if they are clearly in a separate crisis and continue to meet entry criteria. Patients whose symptoms persist for more than 72 hours after fructose or placebo are eligible to receive additional fructose every 6 hours until symptoms subside.

Conditions
-----------------
Sickle Cell Anemia

Intervention / Treatment
-----------------
* Drug: fructose
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Sickle cell crisis requiring hospital admission Crisis began at least 12 hours prior to admission Medical records documenting sickle cell disease and previous crisis requiring hospital visit during the last 24 months available at study site No thalassemia No complex hemoglobinopathy involving thalassemia and sickle cell disease --Patient Characteristics-- Renal: Creatine no greater than 2.2 mg/dL No requirement for regular dialysis Other: Weight above or below 30% of ideal body weight No fructose intolerance No insulin-dependent diabetes No HIV seropositivity No acquired immune deficiency syndrome (AIDS) or AIDS-related illness No general anesthetic for 7 days prior to and 2 days following entry Primary language allows communication with study staff Demonstration of ability to read and understand pain scales required Ability to identify crisis starting time accurately, i.e., to within 6 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: fructose|nan|
|Drug: placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
disease-related problem/condition, genetic diseases and dysmorphic syndromes, hematologic disorders, pain, rare disease, sickle cell anemia